Jin Medical International Ltd. — Form 6-K Summary
Business Context and Reporting Period
Jin Medical International Ltd., a China-based foreign private issuer, filed this Form 6-K for December 2023. The filing, dated December 27, 2023, reports a Nasdaq continued-listing deficiency and related delisting proceedings.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial operating metrics.
Material Changes and Listing Status
- On September 25, 2023, Nasdaq notified the Company that it did not comply with Listing Rule 5550(a)(3), which requires at least 300 public holders for continued listing.
- On December 18, 2023, Nasdaq notified the Company that it had failed to provide a detailed plan supporting additional time for compliance. Nasdaq staff also determined that the Company did not meet the 300 round lot holder requirement for initial listing on the Nasdaq Capital Market.
- Nasdaq initiated delisting procedures. Trading would have been suspended beginning December 28, 2023, unless the Company appealed.
- The Company requested a hearing before the Nasdaq Hearings Panel. On December 20, 2023, Nasdaq confirmed that the delisting action was stayed pending the Panel’s final written decision.
Outlook, Remedial Actions, and Risks
- The Nasdaq hearing is scheduled for March 14, 2024.
- At the hearing, the Company must demonstrate that it can regain compliance with the cited deficiencies and sustain long-term compliance with all applicable Nasdaq maintenance criteria.
- The Company is conducting an internal review with management and external advisors and is exploring remedial actions to regain compliance.
- If the Company believes it has regained compliance before the hearing, it may notify Nasdaq staff and the Hearings Department. If Nasdaq determines that compliance has been restored, the hearing may be canceled.
- The principal disclosed risk is potential delisting and suspension of trading if the Company cannot demonstrate compliance or obtain a favorable Nasdaq decision.
Investor Verification Items
- Verify the Company’s number of public holders and round lot holders against Nasdaq requirements.
- Monitor the March 14, 2024 hearing and Nasdaq’s final written decision.
- Confirm whether the trading suspension remains stayed and whether any delisting or relisting action occurs.
- Review subsequent filings for the Company’s remedial plan, compliance status, and any effects on shareholder liquidity.